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Abstract
Background: Cellular immunity plays a crucial role in cytomegalovirus (CMV) infection and substantial populations of
CMV-specific T cells accumulate throughout life. However, although CMV infection occurs during childhood, relatively
little is know about the typical quantity and quality of T cell responses in pediatric populations.
Methods: One thousand and thirty-six people (Male/Female = 594/442, Age: 0–19 yr.; 959 subjects, 20–29 yr.; 77
subjects) were examined for HLA typing. All of 1036 subjects were tested for HLA-A2 antigen. Of 1036 subjects, 887
were also tested for HLA-A23, 24 antigens. In addition, 50 elderly people (Male/Female = 11/39, Age: 60–92 yr.) were
also tested for HLA-A2 antigen. We analyzed the CD8+ T cell responses to CMV, comparing these to responses in
children and young. The frequencies, phenotype and function CD8+ T cells for two imunodominant epitopes from pp65
were measured.
Results: We observed consistently high frequency and phenotypically "mature" (CD27 low, CD28 low, CD45RA+)
CMV-specific CD8+ T cell responses in children, including those studied in the first year of life. These CD8+ T cells
retained functionality across all age groups, and showed evidence of memory "inflation" only in later adult life.
Conclusion: CMV consistently elicits a very strong CD8+ T cell response in infants and large pools of CMV specific
CD8+ T cells are maintained throughout childhood. The presence of CMV may considerably mould the CD8+ T cell
compartment over time, but the relative frequencies of CMV-specific cells do not show the evidence of a population-
level increase during childhood and adulthood. This contrast with the marked expansion ("inflation") of such CD8+ T
cells in older adults. This study indicates that large scale analysis of peptide specific T cell responses in infants is readily
possible. The robust nature of the responses observed suggests vaccine strategies aimed at priming and boosting CD8+
T cells against major pathogens (including HIV, malaria and CMV itself) could be successful in this age-group.
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Background
Human cytomegalovirus (HCMV) is a widespread β-her-
pesvirus that infects 40% to 100% of adults worldwide
[1]. The common transmission mode of HCMV is vertical:
in almost all cases, HCMV infection occurs during prena-
tal period (transplacental acquisition), at birth (through
exposure to HCMV in the birth canal), or postnatal period
(including transmission by breast milk) [2,3]. In devel-
oped countries, seroconversion for HCMV occurs
throughout life. Primary infection is largely asymptomatic
and HCMV infection persists lifelong usually without
clinical sequelae in healthy individuals. However, recru-
descence of latent infection can cause life-threatening dis-
eases in immunocompromised host, such as transplant
recipients, patients receiving tumor therapy, and patients
with advanced human immunodeficiency virus infection
[1,4]. Moreover, recent studies have shown that primary
HCMV infection can produce severe disease in premature
infants [3,5]. Therefore, studies of human immune
responses to HCMV are required to understand the mech-
anisms involved in control of infection and develop
improved strategies to prevent CMV-induced disease.
Viral infection is usually controlled by a range of innate
and adaptive immune effector mechanisms. In particular,
virus-specific CD8+ cells play a crucial role in the control
of HCMV replication during both acute and chronic
phases [6-8]. Strong virus-specific CD8+ T cell responses
develop during primary infection and functional HCMV-
specific CD8+ T cells are present after resolution of pri-
mary infection. Thereafter, these HCMV-specific CD8+ T
cells are maintained at high frequencies. The proportion
of the HCMV-specific CD8+ T cells in the total lym-
phocyte pool may reach very high levels in elderly individ-
uals [9]. In murine models, accumulation of murine
cytomegalovirus (MCMV) -specific CD8+ T cells was seen
in all organs, starting some time after resolution of pri-
mary infection [8]. This phenomenon, termed "memory
inflation", was also observed in human adults [9]. These
observations are consistent with the idea that continuous
or repetitive exposure to antigens slowly moulds memory
T cell populations over time.
The "phenotype" of virus-specific CD8+ T cells can be
described using a few distinct subsets based on cell surface
markers (CD28, CD27, CD45RA, and CD45RO). CD27
and CD28 are T cell costimulatory molecules, which are
differentially expressed on CD8+ T cells under different
conditions of stimulation over time [10-13]. Naïve and
so-called "early-differentiated" cells are characterized by
high expression of the costimulatory molecules CD28 and
CD27, which may progress through CD28-CD27+ and on
to CD28-CD27- cells, typical of both HCMV and MCMV,
considered to be at a "late" stage of differentiation [14].
Similarly, isoforms of CD45, leukocyte common antigen,
can be used as a cell surface marker to examine differenti-
ation status. In human cord blood, almost all CD8+ cells
show high expression of CD45RA, while the proportion
of cells expressing CD45RO increases with age [15].
HCMV-specific CD8+ cells show high expression of
CD45RO during primary HCMV infection, but are rela-
tively enriched in CD45RA+ cells during the chronic
phase of HCMV infection [14,16,17]. This is thought to
correlate either with a "terminally differentiated" status,
or entry into a program of a long term quiescence and sur-
vival.
Little detail is available on the frequencies, phenotype and
function of antiviral CD8+ T cells in pediatric popula-
tions. It was previously considered that infants may fail to
mount Th1 type responses of a quality similar to those
seen in adults, although emerging data from smaller stud-
ies has led to a revision of these ideas. A recent study
showed that a mature and functional CD8+ T cell
response to HCMV was observed in specific cases of infec-
tion of fetuses and newborns [18]. However, it is unclear
what the normal response is in larger, asymptomatically
infected pediatric populations, and how these popula-
tions evolve through childhood. Immaturity of CD4+ T
cell help, regulation, dendritic cells or innate immunity
could all potentially have an important impact on long-
term maintenance of antiviral CD8+ T cell populations.
Furthermore, several features of the expanded popula-
tions of CD8+ T cells associated with persistent virus
infection have been likened to "ageing", and thus study of
such CD8+ T cells in an infant population might provide
some insights into the induction and maintenance of
"normal" memory in adults [19]. Analysis of pediatric
populations has been hindered to date by largely by limi-
tations on the blood sampling available, but recent
advances in analysis of CD8+ T cells has meant high qual-
ity data may be obtained from as little as 100 μl of blood
[9].
In this study, a large cross-sectional analysis was per-
formed to clarify the status of HCMV specific CD8+ T cells
in infants and children. In order to quantify HLA-
restricted HCMV-specific CD8+ T cells, we used human
leukocytic antigen (HLA)-A2 and HLA-A24 tetrameric
complexes (tetramers) loaded with the immunodominant
peptide derived from HCMV structural protein pp65. In
addition, effector functions of HCMV-specific CD8+ T
cells in children were assessed using IFN-γ enzyme-linked
immunospot (ELISPOT) assay and intracellular cytokine
staining (ICS) for IFN-γ-producing cells. Furthermore, we
evaluated the differentiation status using cell surface
markers (CD28, CD27, CD45RA, and CD45RO) to clarify
the phenotype of the HCMV-specific CD8+ T cells and any
changes over time. We show that the effector functions of
HCMV-specific CD8+ cell in infants are as strong as thoseImmunity & Ageing 2006, 3:11 http://www.immunityageing.com/content/3/1/11
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in young adults. Moreover, the phenotype of HCMV-pos-
itive CD8+ T cells is well differentiated in infants and
young children.
Materials and methods
Study population
Between March and September 2003, blood samples were
taken from patients who attended pediatric clinics at
National Defense Medical College (Tokorozawa, Japan),
International University Health and Welfare (Atami,
Japan), and Hokkaido University (Sapporo, Japan) due to
various diseases. Informed consent was taken from them
or their parents. One thousand and thirty-six people
(Male/Female = 594/442, Age: <1yr.; 132, 1–5yr,; 305, 6–
10yr.; 216, 11–15yr.; 218,; 16–19 yr.; 88, 20–29 yr.; 77)
were enrolled in this study. All of 1036 subjects were
tested for HLA-A2 antigen. Of 1036 subjects, 887 (Male/
Female = 519/368, Age: <1yr.; 115, 1–5yr,; 279, 6–10yr.;
190, 11–15yr.; 172,; 16–19 yr.; 68, 20–29 yr.; 63) were
also tested for HLA-A23, 24 antigens. In addition, 50 eld-
erly volunteers (Male/Female = 11/39, 60–69yr.; 6, 70–
79yr.; 8, 80–89yr.; 22, 90–92 yr.; 14) were also enrolled in
this study. None of them was examined for HCMV sero -
status.
Monoclonal Abs and peptides
Anti-HLA-A2-fluorescein isothiocyanate (FITC), anti-
CD8-peridinin chlorophyll protein (PerCP), anti-CD27-
FITC, anti-CD28-:allophycocyanin (APC), anti-CD45RA-
FITC, anti-CD45RO-APC, anti-IFN-γ-FITC mAbs, and iso-
type control Abs were purchased from Becton Dickinson
PharMingen (San Diego, CA, USA). Anti-HLA-A23, 24
mAbs were purchased from One Lambda (Canogo Park,
CA, USA). Goat anti-mouse IgG-FITC Abs were purchased
from Immunotech (Marseille, France). The HLA-A*0201-
restricted HCMV-specific CTL epitope pp65 495–503
(NLVPMVATV) and HLA-A*2402 restricted HCMV-spe-
cific CTL epitope pp65 328–336 (QYDPVAALF) both pre-
viously identified [20,21], were purchased from MBL
(Nagoya, Japan).
HLA-peptide tetrametric complexes
HLA class I-peptide tetramers were synthesized as
described previously [22]. Briefly, recombinant HLA class
I proteins (HLA-A*0201 and HLA-A*2402) were
expressed and produced in Escherichia coli. The A24-
expressing plasmid was provided by Dr. Kuzushima
(Aichi Cancer Center Research Institute, Japan) refolded
with β2-microglobulin and peptide. After refolding of the
HLA class I molecle, β2-microglobulin and peptide, the
complex was purified by FPLC and biotinylated by Bir A
enzyme (Avidity, Denver, CO, USA). HLA class I-peptide
complexes were mixed with phycoerythrin (PE)-labeled
streptavidin at a molar ratio of 4: 1 to form HLA-peptide
tetrametric complexes. Tetramers were titrated against
peripheral mononuclear cells (PBMCs) from HCMV-sero-
positive and mismatched donors to determine the con-
centration that induced maximal staining with minimal
background.
Cell surface and intracellular staining
HLA typing
Detection of HLA-A2 and HLA-A24 was performed by
flow cytometry using the HLA-A2 and HLA-A23, 24 mAb.
In brief, 20 μL of EDTA or heparinized whole blood was
stained with anti-HLA-A2-FITC and HLA-A23, 24 mAb for
20 minutes at 4°C respectively. After staining with anti-
HLA-A2-FITC mAb, red blood cells were lysed using FACS
lysis (Becton Dickinson Sciences, San Jose, CA, USA).
Whole blood stained with anti-HLA-A23, 24 mAb was
washed with PBS. After the incubation for 20 minutes at
4°C with FITC-labeled mouse IgG, it was washed again
with PBS and lysed using FACS lysis solution (Becton
Dickinson Sciences).
Tetramer staining
50 μL of whole blood was stained with tetramer for 15
minutes at 37°C, followed by addition of titrated Abs
(FITC-, PerCP-, or APC- conjugated) directed against sur-
face molecules and incubation for 20 minutes at 4°C.
Samples were lysed as described above.
Intracellular cytokine staining
To determine the frequencies of IFN-γ-producing peptide-
specific T cells in peripheral blood, intracellular staining
was conducted on fresh whole blood. Frequencies of IFN-
γ-producing peptide-specific T cells were quantified after
stimulation with the CMV HLA-A2 peptide (pp65 495–
503, NLVPMVATV), according to the protocol of the sup-
plier (Becton Dickinson Bioscience, San Jose, CA, USA).
Briefly, heparinized whole blood were stimulated with
peptide (at 10 μM final concentration) for 6h at 37°C in
the presence of Brefeldin (Sigma-Aldrich) at 10 μL/ml.
Whole blood was stained with anti-CD8-PerCP Ab for 20
minutes at room temperature. Whole blood was lysed and
fixed using FACS lysis solution (Becton Dickinson
PharMingen), permeabilized using FACS permeabiliza-
tion buffer (Beckton Dickinson), and then stained with
FITC-labeled IFN-γ or FITC labeled IgG-isotype control
mAb.
Cell were stored in Cell Fix buffer (Becton Dickinson
Immunocytometry systems) at 4°C until analysis. Sam-
ples were analyzed with a FACS Calibur (Becton Dickin-
son Bioscience) using CellQuest software (Becton
Dickinson Bioscience), after compensation was checked
using freshly stained PBMCs.Immunity & Ageing 2006, 3:11 http://www.immunityageing.com/content/3/1/11
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Elispot assays
PBMCs were isolated from heparinized venous blood by
density gradient sedimentation using Ficoll-Hypaque
(Lymphoprep; Axis Shield, Oslo Norway). Fresh PBMCs
were plated in 96-well polyvinylidene plates (Milipore,
Bedford, MA, USA) that have been precoated with 0.5 μg/
ml anti-IFN-γ-mAb (Mabtech, Stockholm, Sweden). The
peptides were added in a volume of 10 μl and then PBMCs
were added at 50,000–100,000 cells/well in a volume of
190 μl. The final concentration of HLA-A2 peptide (NLVP-
MVATV) was 5 μM. The plates were incubated overnight at
37°C, 5% CO2 and washed PBS before addition of the
second, biotinylated anti-IFN-γ mAb (Mabtech) at 0.5 μg/
ml and incubated at room temperature for 100 min. After
washing, streptavidin-conjugated alkaline phosphatase
(Mabtech) was added at room temperature for 40 min-
utes. Individual cytokine-producing cells were detected as
dark spots after 20-minutes reaction with 5-bromo-4-
chloro-3-indolyl phosphate and nitro blue tetrazolium
using an alkaline phosphatase-conjugated substrate (Bio-
Rad Laboratories, Hercules, CA, USA). The number of spe-
cific T cells was calculated by subtracting the negative con-
trol values and expressed as either the number of spot-
forming units per 106 PBMC.
Statistical analysis
Frequency distributions were compared using the Yates
corrected chi-square test or Fisher's exact test. A p value of
0.05 or less was considered to indicate statistical signifi-
cance. For nonparametric statistical analyses, Spearman
rank correlation test were used. All p values were 2-tailed
and considered significant if <0.05. Nonparametric
Mann-Whitney  U  tests were used for data pairs and
Kruskal-Wallis tests were used for group data. Results were
presented using Prism (GraphPad, San Diego, CA, USA).
Results
Frequency of HLA-A2 and A24
Of 1036 subjects, 448 (43%) were positive for HLA-A2. Of
887 subjects, 519 (58%) people were positive for HLA-
A23, 24, of which 76 (15%) were also positive for HLA-
A2. Because it is well established that HLA-A23 antigen is
very rarely detected in Japanese populations [23,24], the
HLA-A23, 24-positive subjects were considered to be pos-
itive for HLA-A24. To compare with children and young
adults, additionally 50 elderly people were enrolled in
this study. All of them were in good health. Of these eld-
erly people, 21 (42%) were positive for HLA-A2.
Frequency of HCMV tetramer-positive responses at 
different ages
Initially, a cross-sectional analysis of HCMV-specific
CD8+ T cell frequency was performed. Analysis of HLA-A2
negative and HLA-A23, 24 negative samples provided a
cut-off for detection of 0.05% and 0.04% of CD8, respec-
tively, as previously obtained [9] (data not shown). Fig 1
shows an example of positive tetramer staining in HLA-
A2+ and HLA-A24+ infants. Of 448 HLA-A2-positive sub-
jects, HCMV-A2 tetramer staining revealed positive
responses in 190 (42%). Of 519 HLA-A23, 24-positive
subjects, HCMV-A24 tetramer staining revealed positive
responses in 133 (26%).
Table 1 shows the results of the HCMV-A2 tetramer assay
in individual age-groups. The percentage of the HLA-A2
subjects, who were positive for HCMV-A2 tetramer, was
31% in 0–4 yr. group, and increased gradually with age,
such that approximately half the adults and elderly popu-
lations were positive. However, the mean percentage of
CD8+ T cells stained with HCMV-A2 tetramer did not
show a continuous increase with age. Indeed, the mean
percentage of CD8+ T cells stained with HCMV-A2
tetramer of the 0–4 yr. group was slightly higher than that
of the 5–9 yr. group and the 10–14yr. group. In order to
confirm that elderly individuals could show a high fre-
quency of HCMV specific CD8+ T cells in Japan, 50 elderly
individuals were examined. The mean frequency of
HCMV-specific CD8+ T cells in elderly group was as high
as that in the previous study [9] and significantly higher
than that in any other groups.
The results of HCMV-A24 tetramer staining are shown in
Table 2. Although the percentage of HCMV-A24 tetramer
positive subjects increased gradually with age, the percent-
Example of CMV tetramer staining in infants Figure 1
Example of CMV tetramer staining in infants. A symp-
tomatic 2-month-old HLA-A2+ infant (A) and an asympto-
matic 1-month-old HLA-A24+ infant (B) were stained with 
pp65 tetramer. The plot shown is gated on live lymphocytes 
and reveals a frequency of HCMV-specific CD8+ T cells. 
HLA-A2 tetramer/CD 8+ lymphocytes was 1.51% in the 
HLA-A2 infant and 0.87% in the HLA-A24+ infant.
CD8
Tetramer
A B
1.51 % 0.87 %Immunity & Ageing 2006, 3:11 http://www.immunityageing.com/content/3/1/11
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age of the HLA-A24 tetramer positive subjects was 19% in
the 0–4 yr. group, which was lower than that of compara-
ble HLA-A2 tetramer positive subjects (31%), and this
remained similar across all age groups. Unlike the HLA-
A2-specific responses, an increase was not observed in the
mean percentage of HLA-A24 tetramer-positive cells in
young adults, although in this case an elderly population
was not tested. Interestingly, as for the HLA-A2+ individ-
uals, the mean percentage of CD8+ T cells stained with
HCMV-A24 tetramer in the youngest group (0–4 yr.) was
higher than that at later ages. Taken together, those find-
ings suggest that young children have cellular immune
responses to CMV comparable to those in young adults.
Seventy-six individuals were positive for both HLA-A2
and HLA-A24. Of 76 subjects, 17 were positive for both
HCMV-A2 and -A24 tetramer staining. The mean fre-
quency of HCMV-specific CD8+ T cells in HLA-A2 and
HLA-A24 individuals was 1.09 and 0.09, respectively. Of
76 subjects, 12 and 8 were positive for HCMV-A2 and -
A24 tetramer staining, respectively. The remainings were
negative for trtramer staining. There was no significant
difference in positive rate of HCMV tetramer between two
alleles and one allele (HLA-A2, A24 vs. HLA-A2; p = 0.79,
HLA-A2, A24 vs HLA-24; p = 0.15). These findings suggest
that HLA type did not influence the immunodominance
using tetramer assay.
Analysis of CD8+ T cell responses in infants and young 
children
To assess in detail the results of HCMV tetramer staining
in the key population of infants and young children, the
youngest group was further divided by age and analyzed
(Table 3, 4). Here, the percentage of HCMV tetramer pos-
itive subjects increased slightly with age. Under 1 year of
age, 23% and 17% were positive for HCMV tetramer stain-
ing in HLA-A2 subjects and HLA-A24 subjects, respec-
tively. The youngest subject who was positive for HCMV
tetramer staining in the HLA-A2 and HLA-A24-positive
population, were 2- and 1-months-old, respectively (Fig-
ure 1). Although the 2 month-old girl was referred to our
hospital due to jaundice, the 1-month old baby had no
symptoms. On the other hand, the mean percentage of
HCMV tetramer-positive cells amongst total lymphocytes
or amongst CD8+ T cells had a slight decrease with age,
lowest at around 3–4 years. These findings are consistent
with prevalent primary HCMV infection in early life was
and confirm that strong HCMV-specific CD8+ T cell
responses can be reproducibly generated in the first year
of life.
Correlation between tetramer and functional assays
To evaluate the effector function of the HCMV-specific
cells, we performed IFN-γ ELISPOT assays and compared
these with tetramer staining. Fifty-six HLA-A2+ subjects
(age: from 3 months to 29 year-old, mean 10.5 years old)
and 17 HLA-A24+ subjects (age: from 1 months to 23
years old, mean 8.9 years old) were selected for ELISPOT
assays. A comparison of the ELISPOT assay and tetramer
assay is shown in Figure 2. Although the number of HLA-
A24+ subjects was small, the comparison of ELISPOT
assay and tetramer assay demonstrates a strong associa-
tion (HLA-A2: p < 0.0001, γ = 0.69 ; HLA-A24: p = 0.0011,
γ = 0.72). We also performed ICS for IFN-γ for HLA-A2+
subjects (n = 33, age: from 2 months to 29 years old, mean
10.1 year-old). A comparison of the ICS and tetramer
assays is shown in Figure 3. Although the association was
not quite as strong as the correlation between ELISPOT
assay and tetramer assay, a significant association was
observed (γ = 0. 55, p = 0.001). The results of ELISPOT
Table 1: Summary of HCMV-tetramer in HLA-A2 individual groups
Age(yr.) (n = 469) 0–4 (n = 179) 5–9 (n = 97) 10–14 (n = 94) 15–19 (n = 50) 20–29 (n = 28) 60–92 (n = 21)
Number of tet(+) 55(31%) 43(44%) 49(52%) 28(46%) 15(54%) 12(57%)
CD8(%) 18.9 ± 4.7 21.5 ± 7.4 20.2 ± 6.9 20.3 ± 6.7 24.8 ± 7.1 23.2 ± 9.6
Tet(%) 0.19 ± 0.23 0.18 ± 0.25 0.22 ± 0.31 0.23 ± 0.19 0.41 ± 0.54 1.49 ± 1.79
Tet/CD8(%) 1.05 ± 1.30 0.85 ± 1.04 1.02 ± 1.36 1.14 ± 0.96 1.55 ± 1.71 5.76 ± 4.19
HCMV-tetramer positive: Tet/CD8(+) Lymphocytes ≥ 0.05%
Table 2: Summary of HCMV-tetramer in HLA-A24 individual groups
Age(yr.) (n = 519) 0–4 (n = 202) 5–9 (n = 106) 10–14 (n = 108) 15–19 (n = 58) 20–29 (n = 45)
Number of tet(+) 39(19%) 32(30%) 23(21%) 24(41%) 15(33%)
CD8(%) 20.0 ± 5.7 18.6 ± 5.1 19.5 ± 6.9 22.3 ± 8.3 24.8 ± 6.4
Tet(%) 0.05 ± 0.07 0.02 ± 0.03 0.02 ± 0.01 0.04 ± 0.06 0.03 ± 0.03
Tet/CD8(%) 0.21 ± 0.31 0.12 ± 0.10 0.15 ± 0.24 0.14 ± 0.16 0.12 ± 0.10
HCMV-tetramer positive: Tet/CD8(+) Lymphocytes ≥ 0.04%Immunity & Ageing 2006, 3:11 http://www.immunityageing.com/content/3/1/11
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assays in HLA-A2 subjects were stratified by age and
shown in Figure 4. The mean spot number of the 0–4 yr.
group was 79.7/106 cells, and although this varied slightly
with age there was no statistically significant difference
between groups. These data indicate that a functional
CD8+ T cell response to HCMV consistently develops in
early life and is sustained throughout childhood.
Expression of phenotypic markers (CD28/27 and CD45RA/
RO) on HCMV-specific CD8+ cells
To identify the differentiation status of HCMV-specific
CD8+ T cells in individual groups, we studied the expres-
sion of CD28, CD27, CD45RA, and CD45RO on periph-
eral blood tetramer+ CD8+ cells using four-color flow
cytometry. Both HLA-A2+ and HLA-A24+ subjects were
included in this analysis, the results of which are shown in
Table 5. These indicate that CD28/CD27 expression on
HCMV-specific CD8+ cells was divided amongst 4 sub-
sets. In the youngest three groups (0–4 yr., 5–9 yr., 10–14
yr.), the predominant phenotype of HCMV-specific CD8+
T cells was the CD28-CD27+ T-cell subset. Although the
CD28+CD27+ subset, ("early" differentiated), was pre-
dominant amongst HCMV specific CD8+ T cells in infants
under 12 months (n = 13, data not shown), beyond this
time, the CD28-CD27+ subset predominated, and these
phenotypes remained relatively stable throughout child-
hood and early adulthood. However, in the elderly group,
the proportion of CD28-CD27- cells ("late differenti-
ated") showed a significant increase. Interestingly, a rare
subset of previously unclassified CD28+CD27- T cells
population increased with age continuously and repre-
sented 22.0% of tetramer+ CD8+ T cells in the elderly peo-
ple.
Table 6 shows the results of expression of CD45RA and
CD45RO on tetramer+ CD8+ T cells. CD45RA+CD45RO-
T cells were predominant in all groups. The proportion of
each phenotype in individual groups did not change.
Therefore, no specific phenotypic patterns of CD45RA
and CD45RO related to the age of the subjects were
observed in tetramer-positive CD8+ T cells.
Discussion
In this study, we adapted immunological techniques
which have been widely applied to the study of adults to
a large pediatric population of over 1000 children. The
aim of the study was to define the quantity and quality of
antiviral responses in early infection and relate any
changes in these to age. Long term longitudinal studies of
CMV specific populations are difficult to perform in
healthy pediatric populations; nevertheless, using similar
large scale cross sectional approaches we have previously
observed a clearly dynamic host-virus relationship in
adult infection [9,25].
The pattern of age-related accumulation observed in this
cross-sectional analysis revealed strong responses in the
first year of life, consistent with acquisition of infection
during this period. The acquisition of cellular immunity
can be regarded as a good marker for viral infection, at a
time when serological responses might be confounded by
the presence of maternally transmitted antibody.
In particular, we evaluated in detail the frequencies of spe-
cific CD8+ T cells during the first four years of life (Table
3, 4). The results showed that initial expansion occurred
very early in both HLA-A2 and A24 individuals. These
Table 3: Summary of HCMV-tetramer in HLA-A2 young children
Age(yr.) (n = 179) < 1 (n = 60) 1 (n = 45) 2 (n = 30) 3 (n = 27) 4 (n = 17)
Number of tet(+) 14(23%) 17(38%) 9(30%) 11(41%) 4(24%)
CD8 18.1 ± 5.1 16.7 ± 4.1 22.5 ± 3.5 19.7 ± 4.4 20.1 ± 5.1
Tet(%) 0.20 ± 0.20 0.25 ± 0.32 0.17 ± 0.19 0.15 ± 0.14 0.08 ± 0.05
Tet/CD8(%) 1.16 ± 1.13 1.48 ± 1.78* 0.73 ± 0.77* 0.75 ± 0.65* 0.28 ± 0.26*
HCMV-tetramer positive: Tet/CD8(+) Lymphocytes ≥ 0.05%
*: P values < 0.05
Table 4: Summary of HCMV-tetramer in HLA-A24 young children
Age(yr.) (n = 202) < 1 (n = 66) 1 (n = 46) 2 (n = 38) 3 (n = 25) 4 (n = 27)
Number of tet(+) 11(17%) 11(24%) 7(18%) 4(16%) 6(22%)
CD8 17.0 ± 5.0 20.0 ± 6.9 19.2 ± 4.2 22.3 ± 3.8 24.8 ± 5.6
Tet(%) 0.07 ± 0.08 0.05 ± 0.05 0.06 ± 0.10 0.01 ± 0 0.03 ± 0.03
Tet/CD8(%) 0.34 ± 0.32* 0.16 ± 0.15* 0.28 ± 0.55* 0.05 ± 0.01* 0.11 ± 0.12
HCMV-tetramer positive: Tet/CD8(+) Lymphocytes ≥ 0.04%
*: P values < 0.05Immunity & Ageing 2006, 3:11 http://www.immunityageing.com/content/3/1/11
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findings support the idea that the primary infection with
HCMV commonly occurs during the first or second year of
life as suggested in previous studies [2,26-28]. Long-term
repetitive antigen stimulation through continuous low
level virus reactivation is considered to be responsible for
the maintenance of very high levels of CMV specific "effec-
tor memory" CD8+ T cells thereafter [6-8]. Why such cells
accumulate over time and particularly in the elderly is not
known, nor indeed is their efficacy in containing viral
reactivation or reinfection. In the pediatric and young
adult populations studied here no apparent "inflation"
was seen in our analysis, although typical expanded pop-
ulations were seen in elderly controls. It is possible that
"inflation" of responses only occurs after a certain period
of host-virus interaction, as is the case in MCMV [8]. Alter-
natively it may be missed due to the cross-sectional design
of the study, Overall however, it does appear that for at
least the first couple of decades, the host virus balance
remains roughly in status quo.
In this study, responsiveness in both ICS and ELISPOT
assays was significantly correlated with tetramer staining.
High frequencies of HCMV specific CD8+ cells were
observed in even in 0–2 year-old infants, and, although
the number of infants examined was relatively small,
these findings suggest that infants infected with HCMV
have a functional CD8+ T cell response to HCMV similar
to that in adults. Moreover, all of these infants but one,
who were positive for HCMV tetramer under 1-year-old,
were asymptomatic in this study. Those observations are
consistent with a recent smaller study which showed that
newborns with congenital HCMV infection were asymp-
tomatic and had functional and mature HCMV-specific
CD8+ T cells [18,29]. A recent study reported that IFN-γ
secretion produced by HCMV-tetramer positive T cells in
old individuals was lower than in young individuals [30].
However, the secretion of IFN-γ produced by tetramer
reactive cells in elderly individuals was not compared with
that in young individuals in this study.
Based on an analysis of CD28/CD27 expression, the stage
of "maturation" or "differentiation" of HCMV-specific
CD8+ T cells can be defined. CD28+ CD27+ T cells are
considered to be naïve cells or early-differentiated T cells,
Correlation of HLA-A2 HCMV tetramer staining and IFN-γ Elispot assay Figure 2
Correlation of HLA-A2 HCMV tetramer staining and IFN-γ Elispot assay. (A) 56 HLA-A2+ subjects were studied, 
including children and adults (age: from 3 months to 29 years old, mean ± SD; 10.5 ± 7.3 years). (B) 17 HLA-A24 subjects were 
studied including children and adults (age: from 1 month to 23 years old, mean ± SD; 8.9 ± 8.8 years).
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progressing to CD28-CD27- T cells, thought to be fully
differentiated T cells [10-14]. We had expected that the
predominant phenotype of HCMV-specific CD8+ T cells
in the youngest group might be CD28+CD27+. However,
the CD28-CD27+, intermediate differentiated phenotype,
was predominant (43.2% of CD8+ tetramer positive T
cells). Subsets of CD28+CD27+ (naïve or early-differenti-
ated phenotype) and CD28-CD27- (late-differentiated
phenotype) represented 34.9% and 20.8% of CD8+
tetramer positive T cells, respectively. The same propor-
tion of HCMV-specific T cells was observed in the 5–9 yr.
and 10–14 yr. groups, and also in infants under one-year-
old (data not shown). These findings suggest that
"mature" CD8+ T cells developed consistently in young
infants. In the elderly group, the proportion of CD28-
CD27+ (intermediate-differentiated phenotype) T cells
was decreased, as the proportion of CD28-CD27- (late-
differentiated phenotype) increased substantially. This
finding broadly supports the idea that the lineage differ-
entiation pattern of HCMV specific CD8+ cells is
CD28+CD27+  → CD28-CD27+→ CD28-CD27-,
although it suggests that the movement of cells across this
spectrum is not continuous over time. Interestingly, how-
ever, we also noted a small proportion of CD28+CD27- T-
cells which rose to 22% of tetramer positive CD8+ T-cells
in the elderly group.
Naïve CD8+ T cells express CD45RA, and this is uniformly
expressed in cord blood. While antigen-experienced
CD8+ T cells initially express CD45RO, re-expression of
CD45RA may occur and this has been described as a state
of late or terminal differentiation – although longitudinal
studies of single cells have not been performed. According
to this scheme, it was expected that a subset of
CD45RA+CD45RO- tetramer+ cells would accumulate
with age. In contrast, the CD45RA+CD45RO- subset was
predominant in all of the age-groups, even in the youngest
children and the proportion did not change through life.
There are two possibilities to explain these observations.
First, this state may be driven by continuous interaction
with antigen. However, this hypothesis is not entirely con-
sistent with the results of CD28/CD27 subsets of this
study, in which CD28-CD27- "late" differentiated cells,
were predominant in only the elderly. Alternatively, the
levels of CD45 isoforms expression correlate poorly with
the stages of antigen-driven T cell differentiation. This is
supported by a previous study, which showed that
CD45RA expression was not correlated to the differentia-
tion phenotypes (28). Expression of other cell surface
markers, such as CCR7, CD57 or CD85j might correlate
more closely with the evolution of T cell responses over
time [31-37].
In this study, HLA-A2+ subjects were selected by flow
cytometry using the HLA-A2 mAb. However, the HLA-A2
molecular type of Japanese is classified into three sub-
types. HLA-A*0201, A*0206, and A*0207 representing
10%, 10%, and 3%, of Japanese, respectively [23].
Because the difference among HLA subtypes may in prin-
ciple affect the antigen processing and the presentation of
CTL epitopes in the context of HLA class I molecules, the
magnitude of CTL response might depend on HLA sub-
type [38]. However, the frequency of individuals staining
positive for the HLA-A2 pp65 tetramer was higher than
that in a previous study, in a Caucasian population
expressing predominantly HLA-A*0201 [9]. In addition,
there was no difference in the percentage of tetramer/CD8
in the 20–29-year-old group between the previous study
and this study. Those observations suggest that the differ-
ence among the three subtypes, did not substantially
influence the results of tetramer staining. However, fur-
ther studies are required to determine whether the differ-
ence among HLA-A2 subtypes can influence functional
assays.
CMV sero-status of subjects was not evaluated in this
study. We reported that 77% of HCMV-seropositive HLA-
A2 subjects were positive for CMV tetramer [9]. These
findings suggest that the result of tetramer assay can be
related to sero-status, because tetramer reactive T cells are
memory T cells. However, further studies are required to
assess whether the results of tetramer assays are consistent
with the HCMV sero-status in different population.
Correlation between intracellular interferon-γ staining and  HLA-A2 HCMV tetramer positive cells/CD8+ lymphocytes Figure 3
Correlation between intracellular interferon-γ staining and 
HLA-A2 HCMV tetramer positive cells/CD8+ lymphocytes. 
There were 33 subjects including children, and adults (age: 
from 2 months to 29 years old, mean ± SD; 10.1 ± 8.5 years).
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In previous study [9], we showed "memory inflation" in
an HLA-A2 positive population. However, the subject was
a Caucasioan population. Therefore, there was a possibil-
ity that the frequency of HCMV specific tetramer might be
different in a Japanese population. In order to confirm
"memory inflation" in Japanese, HLA-A2 positive elderly
subjects were tested. In this study, we could confirm that
"memory inflation" was present in a Japanese population.
However, HLA-A24 elderly subjects were not tested
because HLA-A24 subjects were not examined in our pre-
vious study.
In conclusion, the maintenance of large populations of
HCMV-specific CD8+ T cells was observed throughout
childhood, with substantial responses to infection in early
infancy. Overall major age-related changes in tetramer+
CD8+ T cells were not observed in the first two decades of
life and tetramer+ CD8+ cells of young infants showed a
mature phenotype and function similar to that in adults.
These data provide novel insight into the relative maturity
of the infant antiviral response, and the impact of CMV on
the childhood immune system. Additionally, they dem-
onstrate the technical feasibility of detailed cellular
immunological studies in pediatric populations, under-
taken at a large scale as may be applicable in other child-
hood infections and vaccine programs.
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Table 5: Phenotype (CD27, CD28) of tetramer-positive CD8+ cells in individual groups
Age(yr.) (n = 133) 0–4 (n = 31) 5–9 (n = 24) 10–14 (n = 24) 15–19 (n = 29) 20–29 (n = 13) 60–92 (n = 12)
%
CD28(-)CD27(+) 43.2 ± 16.8 42.5 ± 14.9 39.1 ± 14.4 31.3 ± 13.7 31.6 ± 11.9 17.2 ± 14.1
CD28(+)CD27(+) 34.9 ± 23.2 28.9 ± 14.5 26.7 ± 13.4 32.8 ± 16.0 40.6 ± 14.9 28.1 ± 17.2
CD28(-)CD27(-) 20.8 ± 17.0 26.0 ± 18.9 30.0 ± 16.9 31.4 ± 20.0 22.3 ± 12.0 40.0 ± 20.5
CD28(+)CD27(-) 1.1 ± 2.5 2.6 ± 3.2 4.2 ± 8.7 4.5 ± 4.7 5.5 ± 6.6 22.0 ± 24.2
IFN-γ ELISPOT assay of HLA-A2 individuals by age-group Figure 4
IFN-γ ELISPOT assay of HLA-A2 individuals by age-
group. Individuals from different age groups as indicated 
were analyzed for HLA-A2 peptide specific responses using 
ELISPOT as previously. The differences shown were not sig-
nificant.
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